In this current in silico study, firstly, we have conducted in-depth research to explore the nature and clinical relationship of the p53 and MDM2 gene in the formation of brain lower-grade glioma (LGG) cancer by using several cancer data sets and suggested that the MDM2 gene can be a prognostic biomarker for the early stage LGG cancer. This evidence concerns the gene TP53 and cancer.